At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age
In Brief
A Phase 3 clinical trial evaluating MenACWY-CRM and Licensed meningococcal ACWY vaccine for Meningococcal Infections. Completed, enrolled 2,907 participants across 68 sites in 2 countries.
Detailed Summary
To evaluate the safety and immune response of Novartis MenACWY conjugate vaccine when given to healthy children compared to a licensed Meningococcal ACWY polysaccharide-protein conjugate vaccine.
Study Details
Timeline
Interventions
1 injection of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly
2 injections of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly to children 2 to 5 years of age
1 injection of the licensed meningococcal ACWY was administered intramuscularly